ASCO
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
Researchers at ASCO presented data on the genomic differences in tumors based on IHC and imaging, between racial groups, and between primary and metastatic lesions.
With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay
Premium
The Northstar Select comprehensive genomic profiling test uses BillionToOne's proprietary Quantitative Counting Template technology for solid tumors.
Very Few Patients Eligible for Tissue-Agnostic TRK Inhibitors Get Them, Real-World Analysis Shows
Premium
Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.